ON-DEMAND ERA-EDTA 2021 Congress Summary

Anaemia & CKD Insights from the 58th ERA-EDTA Virtual Congress, 5–8 June 2021


Introduction

Anaemia is a well-known and common complication in chronic kidney disease (CKD), and is associated with increased morbidity and mortality, as well as reduced quality of life. It is caused by several complex mechanisms, such as a decrease in endogenous erythropoietin (EPO), iron deficiency, and/or inflammation with elevated hepcidin levels. Patients are frequently treated with erythropoiesis-stimulating agents (ESA) and/or oral or intravenous iron supplementation, but these treatments are sometimes insufficient. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, a novel family of drugs, have been shown to induce an increase in the production of endogenous EPO, improve iron availability, and reduce hepcidin levels.

In this enduring Howitreat.MD Webinar, four international nephrology experts will, through the lens of this year’s ERA-EDTA 2021 congress, review key developments in the field of CKD-related anaemia, including pathophysiology, current and future therapies, trends in patient management, and practice gaps.

Watch Now

Target Audience

This activity is intended for healthcare practitioners with an interest in anaemia and CKD, including (but not limited to) nephrologists, cardiologists, internists, endocrinologists, and primary care practitioners.

Learning Goals

Patients with CKD, both dialysis- and non-dialysis-dependent, frequently present with anaemia. Clinicians need to be aware of the latest scientific and therapeutic developments in this area in order to be able to provide effective, evidence-based treatment. On the other hand, due to a variety of reasons, notably the COVID-19 pandemic, clinicians may not be able to attend learning events. Therefore, this Live Webinar aims to provide a summary of the latest, most relevant scientific developments, practice guidelines, and treatment strategies, in order to improve the outcomes of patients with CKD-related anaemia.

Objectives

  • Describe current treatments and unmet needs in CKD-related anaemia
  • Evaluate the impact of anaemia on cardiovascular risk in patients with CKD
  • Analyse different available treatment options, particularly with regard to the use of HIF-PH inhibitors versus standard-of-care treatment
  • Understand the role of HIF-PH inhibitors in treating CKD-related anaemia
  • Describe the most frequent treatment-emergent adverse effects of different drugs used in the treatment of CKD-related anaemia
  • Critically assess the most recent/important clinical trials on the treatment of anaemia in CKD, with particular focus on communications presented at ERA-EDTA 2021 Virtual Congress


Faculty:

  • Dr. Pablo Ureña Torres

    Paris, France (Chair)

  • Prof Evgeny Shutov

    Moscow, Russia

  • Prof Francesco Locatelli

    Lecco, Italy

  • Dr Mustafa Arıcı

    Ankara, Turkey

Financial Disclosures

This independent medical education meeting has been funded by Astellas. Astellas has provided funding for speaker fees and organisational costs.

The educational programme has been developed by SEI Healthcare LLC with support from the ERA-EDTA and the relevant communication authors. No members of SEI Healthcare LLC have reported any relevant personal financial relationships.

Speakers’ disclosures

  • Dr. Ureña Torres has participated in clinical research from Amgen, GSK, Astellas. Provided consultancy on advisory boards to Amgen, Astellas, Léo Pharma. He has received speaker’s honoraria from Amgen, Baxter, Fresenius, Sanofi, Léo Pharma, and Vifor Pharma.
  • Prof. Shutov has received speaker’s honoraria from, and provided consultancy on advisory boards for, Amgen, Astellas, and Frenesius Kabi.
  • Prof. Locatelli has provided consultancy on advisory boards for Amgen, Astellas, AstraZeneca, Baxter, FibroGen, GSK, Norgine, Otsuka, Roche, and Vifor-Pharma. He has received speaker’s honoraria from participating in meetings supported by unrestricted grants from Akebia, Amgen, Astellas, AstraZeneca, Bayer, B. Braun, Roche, and Vifor-Pharma.
  • Prof. Arıcı has received speakers’ honoraria from Amgen, Astellas, AstraZeneca, Bayer, Baxter, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Sandoz, and Sanofi.

CME Reviewer

August Felix, BSc MSc
Director of Independent Education, SEI Healthcare 
Disclosure: August Felix has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer-reviewed and the reviewer has disclosed no relevant financial relationships.

Editor

Rita Aresta, MD
Scientific Content Lead, SEI Healthcare 
Disclosure: Rita Aresta has disclosed no relevant financial relationships.

Accreditation statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and SEI Healthcare LLC.

Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™️. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Expiration Dates

The deadline to complete the evaluation form is 31st September 2022.